GlobalData on MSN

Telix doses first patient in TLX591-Px prostate imaging trial

Up to 105 Japanese men will be enrolled at 11 sites, with data aimed at supporting a future marketing authorisation ...

First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in the ...
Crain's Chicago Business

GE HealthCare expands in Japan with prostate cancer diagnostic deal

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. GE HealthCare this morning announced an exclusive ...
FierceBiotech

Lantheus hands GE HealthCare the rights to its blockbuster prostate cancer PET tracer in Japan

Lantheus has inked a deal giving GE HealthCare the rights to carry its prostate cancer PET imaging agent in Japan, with the latter planning to pull it up through its recent acquisition of one of the ...